What Is PSA and Why Does It Matter During Lu-177 PSMA Therapy?
PSA stands for prostate-specific antigen. It is a protein made by the prostate gland. Small amounts of PSA normally leak into the bloodstream. When prostate cancer is active, cancer cells produce more PSA, which raises your PSA level in a way doctors can measure with a simple blood test.
Doctors use PSA as a marker to track how your cancer is behaving. A rising PSA suggests cancer cells are multiplying. A falling PSA suggests a treatment is working. According to the Prostate Cancer Foundation, PSA is one of the main tools used to monitor how men with advanced prostate cancer respond to therapy, whether they receive hormone treatment, chemotherapy, or radioligand therapy.
During Lu-177 PSMA therapy, your care team draws blood to check PSA before each treatment cycle and sometimes between cycles. Watching how PSA changes tells your oncologist whether the treatment is reaching and affecting cancer cells.
How Lu-177 PSMA Therapy Works and the PSA Connection
Lu-177 PSMA therapy is a type of radioligand therapy. It combines a targeting molecule with a radioactive payload. The molecule travels through the body searching for cells with high levels of PSMA, a protein on the surface of most prostate cancer cells. Once it attaches, it delivers radiation from within to kill or slow those cells.
Because cancer cells produce PSA, a drop in PSA after therapy may show that those cells are being damaged or destroyed. This is not a perfect measure. A small number of prostate cancer cells can lose the ability to make PSA even as the disease continues. But PSA remains one of the most widely used markers of treatment response in advanced prostate cancer.
For more on how this therapy targets tumors and what response timelines typically look like, see our related article: How Long Until Lu-177 PSMA Shrinks Your Tumor — What Response Timelines and Scans Show About Treatment Success.
When Do PSA Changes Typically Begin?
Most observable PSA changes happen within the first one to two months after starting therapy. A peer-reviewed analysis through NIH/PMC found that approximately 79% of patients had a PSA decline after their first cycle of Lu-177 PSMA treatment, with levels measured around eight weeks after the initial infusion. This shows that early signs of response, or lack of it, may appear relatively quickly.
That said, every person responds differently. Some patients see a clear drop after the first infusion. Others may need two or three cycles before the numbers change much. Your oncologist will look at the pattern of change across multiple readings before deciding how well the treatment is working for you.
It's also important to understand that PSA changes and physical tumor changes often don't happen at the same pace. Imaging scans, particularly PSMA PET-CT scans, provide a separate view of what is happening in your body. Your care team uses both together to get the complete picture.
What a PSA Decline May Mean for Your Prognosis
A meaningful drop in PSA during therapy is generally an encouraging sign. In clinical research, a decline of 50% or more from your starting PSA level, often called a PSA50 response, is used as a benchmark for significant biochemical response to treatment.
A study in PubMed examined PSA response in patients receiving Lu-177 PSMA treatment for castration-resistant prostate cancer. It found that around 45% of patients had a PSA decline of 50% or more over the course of treatment. Importantly, these patients lived significantly longer on average than those who didn't respond biochemically. This connection makes PSA monitoring during therapy something your team watches carefully.
Even a smaller PSA decline—for example, 20% to 30%—may still show meaningful disease control. Your care team doesn't focus only on the 50% mark. They look for a consistent downward trend over multiple cycles, along with stable or improved imaging results.
What If PSA Does Not Drop Right Away?
A flat or slowly moving PSA after the first cycle doesn't automatically mean the treatment failed. Some patients show what researchers call a delayed response. PSA doesn't start to fall until the second or third cycle of therapy.
This matters because Lu-177 PSMA therapy typically involves four to six treatment cycles spaced about six weeks apart. Judging a response too early, after only one cycle, may not show how well the treatment will work for you. Your oncologist will generally want to see the PSA trend across at least two or three cycles before making major decisions about whether to continue, adjust, or change your treatment plan.
During this waiting period, imaging scans remain important. Sometimes a scan shows stable or even reducing disease before PSA starts to drop. Your team looks at all the information together rather than relying only on PSA numbers.
PSA Flare — Does It Happen With Lu-177 PSMA Therapy?
You may have heard about PSA flare: a temporary rise in PSA shortly after starting a treatment, which then falls as the body responds. This happens with some hormone therapies and immunotherapy treatments.
With Lu-177 PSMA therapy, a true PSA flare is uncommon based on available research. A clinical review found PSA flare during Lu-177 PSMA treatment is very rare. This means that if your PSA rises during this therapy, it likely shows real disease activity, not a temporary response that will go away.
That said, your oncologist won't interpret a single PSA reading on its own. A small early rise may trigger closer monitoring and imaging review before your treatment plan changes.
What a Sustained PSA Rise May Signal
A consistent and meaningful PSA increase across two or more consecutive measurements, especially if accompanied by changes on imaging or worsening symptoms, shows the cancer may be progressing despite treatment. Doctors define PSA progression as a rise of at least 25% from the lowest PSA level reached, plus an actual increase in the PSA number.
A study examined early PSA changes in patients receiving Lu-177 PSMA-617 therapy. Patients whose PSA went up at six weeks after their first cycle were significantly more likely to continue progressing at twelve weeks. This suggests that the early direction of PSA movement can predict longer-term outcomes, which is why your early lab results matter clinically.
If PSA rises consistently, your oncologist will typically recommend imaging to see what's going on before deciding next steps. A PSA increase alone doesn't immediately stop treatment. It prompts your team to carefully review everything before deciding what to do.
PSA Is One Piece of a Larger Picture
During Lu-177 PSMA therapy, your care team tracks more than PSA alone. To fully understand how treatment is working, your team uses several different measures together:
- Alkaline phosphatase (ALP): A blood marker that shows activity in bone cancer spread and is often high in men with cancer in their bones
- Lactate dehydrogenase (LDH): A general marker of cell turnover and overall disease in the body
- Complete blood count (CBC): Tracks red blood cells, white blood cells, and platelets, all of which can change from radiation during therapy
- PSMA PET-CT scans: Imaging that shows where PSMA-positive tumor tissue is located and tracks how it responds to therapy over time
- CT or MRI scans: Used to measure changes in soft tissue lesions, lymph nodes, and other areas PSA may miss
The Prostate Cancer Foundation notes that PSA monitoring is a standard part of tracking advanced prostate cancer, but it means more when combined with imaging results and your doctor's physical exam and how you feel. No single number tells the whole story.
What the VISION Trial Tells Us About PSA and Survival Outcomes
The VISION trial was a large, randomized phase III clinical study of Lu-177 PSMA-617 in men with metastatic castration-resistant prostate cancer who had already tried hormone therapy and taxane chemotherapy. Its results showed this therapy could help this patient group.
According to data summarized by the Prostate Cancer Foundation, patients who received Lu-177 PSMA-617 alongside standard care lived a median of 15.3 months, compared to 11.3 months in the standard care group. Imaging-based progression-free survival was also significantly longer: 8.7 months versus 3.4 months in the control group.
PSA response was tracked alongside these survival outcomes. Studies before and after confirmed what earlier research had shown: patients who achieve a meaningful PSA decline during treatment live longer than those whose PSA doesn't drop. This doesn't mean a lack of PSA response guarantees failure, but it tells your team a lot about how treatment is working.
To understand more about what the clinical trial evidence means for your specific treatment decisions, see: What Do the Latest Clinical Trial Results Tell Us About Lu-177 PSMA Therapy for Stage 4 Prostate Cancer — and What Do They Mean for My Treatment?
How Often Will Your PSA Be Measured During Therapy?
Most treatment programs check PSA before each cycle of Lu-177 PSMA therapy. Because a standard course typically involves four to six cycles spaced roughly six weeks apart, you can expect a PSA blood draw approximately every six weeks during active treatment. Some centers also check PSA between cycles if needed, for example if your symptoms change or your oncologist wants to watch a specific trend more closely.
After completing a course of therapy, PSA monitoring continues on a schedule your team sets based on your situation. The goal is to catch any signs of disease progression early enough to plan a response. How often you're tested after treatment depends on how well you responded, whether any further therapy is planned, and the overall state of your disease.
Questions to Ask Your Care Team About Your PSA Results
PSA numbers on a lab report can feel unsettling, especially if they don't show improvement. A few questions that may help you understand your results:
- Is this result part of a consistent trend, or is it a single reading you want to recheck?
- What level of PSA change, in my specific case, would lead you to reconsider the treatment plan?
- What are the imaging results showing right now, and do they match what the PSA is suggesting?
- Are there other blood markers, like ALP or LDH, that you're watching alongside PSA?
- If my PSA continues to rise, what would the next realistic steps look like?
Coming to appointments with prepared questions helps you and your doctor talk clearly about what the numbers mean and what actions they might prompt. Bringing a caregiver or trusted person with you to help take notes can help, especially when absorbing complex information under the stress of a clinical visit.
If you are still researching whether Lu-177 PSMA therapy is an option for you, this plain-language guide can help: Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Guide to Eligibility for Men with Metastatic Castration-Resistant Prostate Cancer.
When to Talk to Your Doctor
Reach out to your oncology care team if your PSA rises significantly between cycles, if you notice new or worsening symptoms, or if you're confused about your results. Don't try to interpret PSA numbers without your care team's input. Your oncologist understands your full situation in a way a general article cannot.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How soon after starting Lu-177 PSMA therapy should I expect my PSA to drop?
Some patients see a PSA decline within the first eight weeks after their initial infusion. Others may not show a clear change until after two or three cycles. Your oncologist will track the trend across multiple readings rather than relying on any single result to judge how therapy is working.
Does a rising PSA always mean the treatment is not working?
Not necessarily, especially very early in treatment. A small, short-term rise in the first few weeks does not automatically signal failure. However, a sustained PSA increase across two or more consecutive measurements — particularly if combined with worsening symptoms or changes on imaging — is a more serious finding that your care team will want to investigate carefully.
What is a PSA50 response and why do doctors use it as a benchmark?
A PSA50 response means your PSA level has fallen by 50% or more from where it started before treatment. Clinical research has found that reaching this threshold is associated with better overall survival outcomes in men receiving Lu-177 PSMA therapy. Doctors use it as one measurable marker of meaningful biochemical response, though smaller declines can still reflect disease control.
Is PSA flare common during Lu-177 PSMA therapy?
No. Unlike some hormone therapies where a temporary PSA spike before a decline has been observed, true PSA flare is considered very uncommon with Lu-177 PSMA therapy based on current research. If your PSA rises during this treatment, your care team is more likely to treat it as a sign of genuine disease activity and will investigate further with imaging.
Is PSA the only way my doctor can tell if Lu-177 PSMA is working?
No. Doctors use PSA alongside PSMA PET-CT scans, standard CT or MRI imaging, and other blood markers such as alkaline phosphatase and lactate dehydrogenase. They also pay close attention to how you feel clinically — whether symptoms like pain are improving or worsening. PSA is one important signal in a broader picture.
What happens if my PSA keeps rising after multiple treatment cycles?
A persistent PSA rise across multiple cycles, combined with evidence of progression on imaging or worsening symptoms, may indicate that the cancer is no longer responding to Lu-177 PSMA therapy. In that case, your care team will discuss what options may be available next — which could include other systemic therapies, clinical trials, or supportive care, depending on your overall health and prior treatment history.